The main aim is to see whether this approach can keep the cancer from returning for a longer time, measured as progression-free survival. After the operation, participants are randomly assigned to receive the liver‑directed treatment together with the usual IV chemotherapy, with treatment cycles given every few weeks and regular clinic visits for monitoring.

During the study, patients have routine scans and blood tests to look for any signs of cancer coming back, to check for side effects, and to answer simple questionnaires about overall health and quality of life. Follow‑up continues for several years to record how long patients stay free of disease and to collect safety information.

Participants in the study will be divided into two groups. One group will receive panitumumab first, followed by regorafenib if the disease progresses. The other group will receive the treatments in the reverse order, starting with regorafenib and then switching to panitumumab if needed. The study will help determine which sequence of treatments is more effective for patients with this type of cancer.

The trial will last for a period of time during which participants will receive the treatments and be monitored for their health and response to the medications. The main goal is to see which treatment sequence helps patients live longer. The study will also look at the side effects of the treatments and how well the cancer responds to them. Participants will receive either the study medications or a placebo, depending on the group they are assigned to.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

The purpose of the study is to compare the effectiveness of two different sequences of these treatments. In the first sequence, patients receive FOLFOX combined with panitumumab, followed by FOLFIRI combined with bevacizumab. In the second sequence, patients receive FOLFOX combined with bevacizumab, followed by FOLFIRI combined with panitumumab. The study aims to determine which sequence is more effective in controlling the cancer over a period of 36 months.

Participants in the study will receive their treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study will monitor the progression of the cancer and the overall survival of the patients over the course of the treatment. The trial will also assess the safety of the treatments by keeping track of any side effects experienced by the participants. The study is expected to continue until June 2025.

Participants in this study will be randomly assigned to receive either ivonescimab or bevacizumab, both given in combination with FOLFOX chemotherapy. The study is designed so that neither the participants nor their doctors will know which treatment is being given, which helps ensure fair comparison of the results. The medications will be given through a vein, which means they are delivered directly into the bloodstream through an intravenous line. During the study, participants will have regular check-ups where doctors will monitor the size of tumors using imaging scans and assess how well the treatment is working. The study will also track any side effects that occur and measure the levels of ivonescimab in the blood at different times.

The study will also collect information about how long participants live overall, how many people respond to treatment, and how long those responses last. Doctors will monitor for any unwanted effects from the medications and check blood tests for abnormal results. For those receiving ivonescimab, the study will also check whether the body develops antibodies against this medication, which could affect how well it works. This study is intended for people who have not yet received treatment for their metastatic colorectal cancer, though previous treatment for earlier stages of the disease is allowed if it was completed more than twelve months before the cancer spread.

The purpose of this study is to evaluate how well these treatment combinations control the disease after 4 months of treatment. FOLFOX chemotherapy includes the drugs fluorouracil, folinic acid, and oxaliplatin, while FOLFIRI chemotherapy includes fluorouracil, folinic acid, and irinotecan. Fruquintinib is taken as capsules by mouth, while the other medications are given through an intravenous infusion into a vein.

The treatment will continue for up to 12 months, with regular medical check-ups and imaging scans to monitor how the cancer responds to treatment. Throughout the study, doctors will track any side effects and how well patients tolerate the treatments. They will also monitor patients’ overall health status and quality of life using questionnaires.

The purpose of this research is to evaluate how well these three medications work together when given as an initial treatment for metastatic colorectal cancer. The study will measure how many patients respond to this combination therapy. Treatment will continue for up to 12 months, with regular medical check-ups to monitor the patient’s health and assess how well the treatment is working.

During the study, trastuzumab deruxtecan and bevacizumab will be given through an intravenous infusion, while capecitabine will be taken as tablets by mouth. Patients will receive regular assessments including physical examinations, blood tests, and imaging scans to monitor their response to treatment and check for any side effects.

Participants in the study will be assigned to one of the two treatment groups through a process called randomization, which is similar to drawing lots to decide which group a person joins. To ensure the results are unbiased, a double-blind method is used, meaning that neither the participants nor the researchers know which specific treatment is being given during the course of the study. The study will monitor how long the cancer remains stable and how long participants live to determine if the new combination is more effective than the current standard treatment.

The treatment groups will receive various medications. One group will receive a combination of pumitamig with several chemotherapy drugs, including oxaliplatin, calcium folinate, fluorouracil, irinotecan hydrochloride trihydrate, and capecitabine. These drugs are administered through different methods, such as an infusion, which is a liquid medicine delivered directly into a vein, or by oral use, which means taking the medicine by mouth. The other group will receive a combination of bevacizumab along with a set of chemotherapy drugs.

The study is divided into two stages. The first stage aims to see how many people experience a reduction in tumor size after receiving the treatment. The second stage focuses on observing how long the treatment keeps the cancer from growing or spreading further. Throughout the process, information is gathered to understand how well the medicines work and how they are tolerated by the body.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

The purpose of this study is to find out if telisotuzumab adizutecan works better than the combination of LONSURF and bevacizumab in treating this type of cancer, and to check how safe the new treatment is. The study will be conducted in two stages. In the first stage, researchers will determine the best dose of telisotuzumab adizutecan and see how well it works and what side effects it causes. In the second stage, a larger group of people will be divided randomly into two groups: one group will receive telisotuzumab adizutecan alone, and the other group will receive LONSURF tablets together with bevacizumab. The study will look at whether the cancer shrinks or disappears, how long people live, and what unwanted effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to 64 weeks. Regular check-ups will be done to monitor the cancer and any side effects through physical examinations, blood tests, and imaging scans. The study will also ask participants questions about their quality of life and how they are feeling. Researchers will measure various aspects of how the body processes telisotuzumab adizutecan, including how long it stays in the body and whether the immune system reacts to it. The study will continue to follow participants to see how long they live and how long their cancer stays under control.

Patients in this study will be divided into two groups, and each group will receive one of the two treatment combinations. The treatments will be given over a period of up to 30 months. Irinotecan and cetuximab are given through a vein, while trifluridine and tipiracil hydrochloride are taken by mouth as tablets, and bevacizumab is given through a vein. The study will look at how well each treatment works by checking if the cancer gets smaller or goes away completely using imaging scans. Doctors will also monitor patients for any side effects from the treatments.

During the study, patients will have regular check-ups that include blood tests, physical examinations, and imaging scans to see how the cancer is responding to treatment. The study will also measure how long patients live without their cancer getting worse and their overall survival time. Additionally, patients will be asked to complete questionnaires about their quality of life to understand how the treatments affect their daily activities and well-being. The study requires patients to have specific genetic characteristics in their cancer, which will be tested using a blood test that looks for cancer cells circulating in the bloodstream.

Patients in this study will be divided into two groups by chance. One group will receive FOLFIRI plus cetuximab continuously without planned breaks. The other group will receive the same treatment for eight cycles, then have a planned break from treatment. If the cancer starts growing again during the break, the treatment will be restarted. The study will track how long the treatment strategy works before it fails, which could happen if the cancer gets worse, if side effects become too severe, if certain resistance markers appear in blood tests, or if death occurs. All medications will be given through a vein as an infusion.

During the study, patients will have regular check-ups and tests to see how the cancer is responding to treatment and to monitor for any side effects. Blood samples will be taken to look for tumor genetic material in the blood, which can help doctors understand if the cancer is responding to treatment or developing resistance. Quality of life will also be measured using questionnaires. The study will compare the two different ways of giving the same treatment to see which approach is better for patients with this type of cancer.

The purpose of this research is to determine if combining BNT314 and BNT327 with chemotherapy is more effective and safe compared to standard treatment with bevacizumab and chemotherapy. BNT314 is given as a solution that goes directly into a vein through intravenous infusion. Similarly, BNT327 is first mixed with liquid and then also given through intravenous infusion.

The study is divided into three parts. The first two parts focus on finding the right dose and checking the safety of the treatment combination. The final part compares how well the new treatment combination works against the standard treatment. Throughout the study, doctors will monitor patients’ responses to the treatment and watch for any side effects that may occur.

The purpose of this research is to determine how well this combination therapy works when given again to patients who have previously benefited from similar treatment but whose cancer has since progressed. The study will measure how long patients remain without their cancer getting worse, particularly during the first four months of treatment.

During this single-group study, all participants will receive both medications. The treatment can continue for up to 36 months, depending on how well it works and how well it is tolerated. Throughout the study, doctors will monitor patients’ health through regular medical examinations and tests to check for any side effects and to see how the treatment is working.

The main purpose of this research is to determine if adding Melphalan treatment to the liver before starting the combination of Trifluridine-tipiracil and Bevacizumab helps to better control cancer growth in the liver compared to using Trifluridine-tipiracil and Bevacizumab alone. Trifluridine-tipiracil is given as tablets by mouth, while Bevacizumab is given through an infusion into a vein.

Throughout the study, patients will have regular medical check-ups and imaging tests to monitor their cancer. These tests will help determine how well the treatment is working and track any changes in the cancer, both in the liver and elsewhere in the body. The study will continue until the cancer shows signs of growth or until other factors require stopping the treatment.

The study will compare two different treatment approaches: one group will receive MK-1084, cetuximab, and mFOLFOX6, while the other group will receive mFOLFOX6 either alone or with another drug called bevacizumab. The main purpose is to determine if adding MK-1084 and cetuximab to standard chemotherapy is safe and effective for treating this specific type of colorectal cancer.

During the study, patients will receive their assigned treatments through a combination of oral tablets (MK-1084) and intravenous infusions (other medications). The medications will be given according to a specific schedule, and patients will be monitored regularly to assess how well the treatment is working and to check for any side effects.

The treatment involves FOLFIRI chemotherapy, which is a standard treatment option for metastatic colorectal adenocarcinoma (a specific type of colorectal cancer). During the study, patients will receive this chemotherapy either every two weeks or every three weeks. The research team will monitor how the cancer responds to treatment using specialized imaging criteria called RECIST (Response Evaluation Criteria in Solid Tumors).

Patients in this study will have their cancer assessed regularly to determine how well the treatment is working. The researchers will track how long patients remain without their cancer progressing, overall survival time, duration of treatment, and any side effects that occur during the study.

The trial is a first-in-human study, meaning this treatment has not been tested in people before. It involves taking a sample of the patient’s tumor tissue through surgery, extracting the tumor-infiltrating lymphocytes, growing them in a laboratory to increase their numbers, and then returning these cells to the patient as a form of treatment. Patients will receive multiple administrations of the CC-38 treatment over the course of the study.

To participate, patients must have colorectal cancer that has spread to other parts of the body (stage IV) or prostate cancer that is either locally advanced (stage III) or has spread to other parts of the body (stage IV). Their disease must have progressed despite previous standard treatments, and they must have measurable disease remaining after the tumor sample is taken for creating the treatment.

The purpose of the study is to evaluate how well these combinations work compared to standard treatments for metastatic colorectal cancer. The study will also assess the safety and tolerability of these combinations, which means checking for any side effects and how well patients can handle the treatment. Additionally, the study aims to find the best dose of telisotuzumab adizutecan to use in future studies. Participants in the study will receive one of the treatment combinations, and some may receive a placebo. The study will last for a period of up to 13 weeks, during which participants will be closely monitored by healthcare professionals.

Throughout the study, researchers will look at various outcomes, such as how long patients live without the cancer getting worse, how long any positive response to the treatment lasts, and overall survival rates. The study will help determine if these new treatment combinations can offer better outcomes for patients with metastatic colorectal cancer. The results will contribute to understanding the potential benefits and risks of these treatments, ultimately aiming to improve care for individuals with this type of cancer.

The purpose of the study is to understand the safety and effectiveness of these combinations in patients who have already tried other standard treatments for their cancer. The study will be conducted in two parts. In the first part, researchers will determine the safest dose of OMTX705 when used with regorafenib and with both regorafenib and tislelizumab. In the second part, the study will evaluate how well these combinations work in controlling the cancer. Some patients will receive regorafenib alone to compare the results.

Participants in the study will receive the treatments through an intravenous infusion, which means the medication is given directly into a vein, and in the case of regorafenib, as oral tablets. The study will monitor the participants’ health, including any side effects and changes in their cancer, over a period of time. The goal is to find out if these new combinations can provide a better treatment option for people with advanced colorectal cancer.

Participants in the study will receive a combination of chemotherapy drugs, which include fluorouracil, oxaliplatin, calcium levofolinate, and irinotecan. These drugs are administered through an infusion, which means they are given directly into the bloodstream. The study will last for a period of up to 12 months, during which the participants will be monitored to assess the response of their cancer to the treatment. The goal is to determine which combination of drugs is more effective in treating metastatic colorectal cancer.

The trial will involve regular imaging tests to evaluate the size and spread of the cancer. These tests will be reviewed by specialists who are not aware of which treatment the participants are receiving, ensuring an unbiased assessment. The study will also monitor the safety of the drugs by checking for any side effects or changes in health. The results of this trial could help improve treatment options for patients with metastatic colorectal cancer.

Participants in the study will be randomly assigned to receive either the combination of Fruquintinib and Tislelizumab or other standard treatments. The study will monitor the participants over a period to see how the cancer responds to the treatment. This includes checking if the cancer stops growing or shrinks, and how long the participants live without the cancer getting worse. The study will also look at the safety of the treatment and any side effects that may occur.

The trial aims to provide more information on how well this combination of treatments works for patients with metastatic colorectal cancer without liver metastases. By participating, researchers hope to find better ways to manage and treat this type of cancer, potentially improving outcomes for future patients. The study will continue until enough data is collected to make a clear conclusion about the effectiveness and safety of the treatment combination.

During the study, participants will receive regorafenib and may also receive other treatments that are commonly used for this type of cancer. These treatments include medications like aflibercept, capecitabine, fluorouracil, bevacizumab, irinotecan hydrochloride trihydrate, oxaliplatin, and calcium levofolinate. Some of these medications are given through an IV infusion, which means they are delivered directly into the bloodstream through a vein, while others are taken orally as tablets.

The study will take place over a period of time, and participants will be monitored to see how their cancer responds to the treatment. The main goal is to determine if regorafenib can help control the cancer and improve the quality of life for patients. Participants will be regularly checked by healthcare professionals to track their progress and any side effects they may experience. The study aims to provide valuable information that could help improve treatment options for people with metastatic colorectal cancer in the future.

The purpose of the study is to explore how effective Vinorelbine is in treating patients with metastatic colorectal cancer. Participants in the study will receive Vinorelbine and will be monitored over a period of time to see how their cancer responds to the treatment. The study will involve regular check-ups and imaging tests, such as computed tomography (CT) scans, to assess the progress of the disease.

The study aims to determine the percentage of patients who experience a reduction in their cancer size or a complete disappearance of the cancer. Additionally, the study will look at how long patients live without the cancer getting worse, overall survival rates, and any side effects experienced during the treatment. The quality of life of participants will also be evaluated to understand the impact of the treatment on their daily lives.

Participants in the study will undergo a biopsy, which is a procedure to remove a small sample of tissue for testing. The study aims to see how well the µCAN test can provide accurate and reliable information to guide treatment decisions. The test results will help doctors choose the most suitable therapy for patients who have not responded to previous treatments. The study will also monitor the safety of the test and any side effects that may occur during the process.

The trial will take place over several years, with the goal of collecting data on how effective the µCAN test is in providing treatment guidance. Participants will be observed for any adverse events related to the test or study procedures, and their experiences with the test will be recorded through a questionnaire. The study will help improve understanding of how to better treat metastatic colorectal cancer using advanced diagnostic tools.

The purpose of the study is to evaluate how well pembrolizumab works in patients with a specific type of metastatic colorectal cancer that has certain genetic characteristics. These patients have already tried standard treatments without success. The study involves a process called “priming,” where temozolomide is used to prepare the cancer cells to respond better to pembrolizumab. This priming phase aims to increase the number of mutations in the cancer cells, which may make them more responsive to the treatment.

Participants in the study will receive pembrolizumab and temozolomide over a period of time, with regular monitoring to assess the response of the cancer to the treatment. The study will also look at the safety and tolerability of pembrolizumab, both on its own and after the priming with temozolomide. The trial is designed to gather information on how long patients live without the cancer getting worse and overall survival rates. The study is expected to continue until June 2025.

The trial is testing two medications, nivolumab and ipilimumab, which are given together as a combination treatment. Nivolumab, also known by its code name BMS936558, and ipilimumab, also known as BMS734016, are both types of drugs called immunotherapies. They work by helping the body’s immune system recognize and attack cancer cells more effectively. The purpose of the study is to evaluate the safety and effectiveness of these two combination treatments over a period of 24 weeks.

Participants in the study will receive the medications through an infusion, which means the drugs are given directly into the bloodstream through a vein. The study will monitor how well the treatments work and any side effects that may occur. The goal is to understand how these treatments can help manage metastatic colorectal cancer with dMMR and MSI features, providing valuable information for future cancer care.

The purpose of the study is to assess the clinical behavior of metastatic colorectal cancer and determine the overall possibility of surgically removing the cancer, as well as to observe any complications after surgery and the outcomes for patients. Participants in the study will receive either Fluorouracil or Capecitabine as part of their treatment plan. The study will monitor the patients over a period to gather information on how well the treatments work and the overall health and recovery of the patients.

This research is important for improving the understanding of metastatic colorectal cancer and finding better ways to treat it. By studying the effects of these medications and the potential for surgery, the study aims to provide valuable insights that could lead to improved treatment strategies and outcomes for patients with this type of cancer.

The purpose of this study is to gather more information about how these medications work together, their safety, and how well they are tolerated by patients. The study will be conducted in two phases. In the first phase, the focus will be on determining the safety and appropriate dosage of the combination treatment. The second phase will assess the effectiveness of the treatment in reducing the cancer. Participants will take the medications and undergo regular check-ups to monitor their health and the cancer’s response to the treatment.

Throughout the study, researchers will collect data on any side effects experienced by participants and how the medications are processed in the body. This information will help in understanding the potential benefits and risks of using galunisertib and capecitabine together for treating advanced colorectal cancer with peritoneal metastases. The study aims to provide valuable insights that could lead to improved treatment options for patients with this challenging form of cancer.

The purpose of this study is to evaluate the safety and effectiveness of this combination treatment in patients who have not received any prior treatment for their metastatic colorectal cancer. The study is divided into two phases. In the first phase, the focus is on determining the safest dose of Arfolitixorin that can be given with the other drugs. In the second phase, the study will look at how well the treatment works in shrinking tumors and controlling the cancer.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor participants for any side effects and measure how the cancer responds to the treatment over time. The goal is to find out if this new combination can be a safe and effective option for treating metastatic colorectal cancer.

The treatments being studied include two different combinations of chemotherapy drugs. The first combination contains Oxaliplatin Fresenius Kabi as a solution for infusion, which can be given up to 200 mg per square meter of body surface area per day. The second combination contains Irinotecan Fresenius Kabi as a solution for infusion, which can be given up to 400 mg per square meter of body surface area per day. Both treatments may be given for up to 12 months.

During the study, small samples of tumor tissue will be collected and grown in a laboratory to create tumouroids. These laboratory-grown samples will be tested to see how they respond to different chemotherapy combinations. This information will help determine which treatment might work better for each patient. The study will track how well patients respond to treatment, how long the treatment keeps the cancer under control, and any side effects that may occur.

The purpose of the study is to evaluate the effectiveness of using Regorafenib in combination with other treatments as an initial therapy before starting chemotherapy for patients with metastatic colorectal cancer. The study will be conducted in two phases. In the first phase, the focus will be on the best response to the treatment, while the second phase will look at overall survival, which means how long patients live after starting the treatment.

Participants in the study will receive the combination of medications for a period of two months. After this initial treatment, they will proceed to receive chemotherapy. The study aims to determine if this approach can improve the response to treatment and increase the survival time for patients with metastatic colorectal cancer. The trial will also monitor the safety and any side effects of the treatments used.

Participants in the study will receive either the combination of D,L-methadone and mFOLFOX6 or mFOLFOX6 alone. The study will be conducted in two phases. The first phase will focus on understanding the safety and appropriate dosage of D,L-methadone when used with mFOLFOX6. The second phase will assess the effectiveness of the combination in controlling the cancer. Some participants may receive a placebo instead of D,L-methadone to compare the outcomes. The study will monitor the response of the cancer to the treatment over a period of 12 weeks.

The trial aims to provide insights into whether adding D,L-methadone to the standard mFOLFOX6 treatment can improve outcomes for patients with advanced colorectal cancer. The study will also look at the overall survival, quality of life, and safety of the treatment. Additionally, researchers will examine the expression of a specific protein called the μ opioid receptor in tumor tissue to see if it affects the treatment’s effectiveness. The study is expected to continue until October 2027.

The purpose of the study is to evaluate whether this combination of medications is effective in treating this specific group of patients. Participants in the study will receive the treatment through an infusion, which is a way of delivering medication directly into the bloodstream. The study will monitor the patients over a period of time to see how well the treatment works and to observe any side effects. The study will also look at how long the treatment remains effective and the overall survival of the patients.

Throughout the study, the effectiveness of the treatment will be assessed using specific criteria to measure the size and growth of the cancer. The study will also track the duration of the patients’ response to the treatment, the time until the cancer progresses, and any toxic effects experienced. The study aims to provide valuable information on the potential benefits of this treatment combination for patients with advanced colorectal cancer.

Participants in the study will receive a combination of medications, including cetuximab, regorafenib, calcium levofolinate, bevacizumab, irinotecan, fluorouracil sodium, oxaliplatin, and Lonsurf (which contains trifluridine and tipiracil hydrochloride). These medications are administered in various forms, such as tablets or infusions, and work in different ways to help fight cancer. Some of these drugs are chemotherapy agents, which kill cancer cells, while others, like cetuximab and bevacizumab, are antibodies that target specific proteins on cancer cells.

The purpose of the study is to determine how effective this treatment plan is in controlling the cancer and to monitor any side effects that may occur. Participants will be monitored throughout the study to assess their response to the treatment and to ensure their safety. The study will also involve the use of a placebo in some cases to compare the effects of the active medications. The trial aims to provide valuable information on the best ways to treat metastatic colorectal cancer with these medications.

The purpose of the study is to compare the effectiveness of using Encorafenib and Cetuximab together with Pembrolizumab against using Pembrolizumab alone. Participants in the study will be randomly assigned to one of these two treatment groups. The study will last for up to 24 months, during which participants will receive their assigned treatment and have regular check-ups to monitor their health and the cancer’s response to the treatment.

Throughout the study, participants will have regular visits with the study team to assess their health, including blood tests and scans to check the cancer’s progress. The study aims to provide valuable information on whether the combination of these medications can offer better outcomes for patients with this specific type of metastatic colorectal cancer. The results could help improve treatment options for future patients with similar conditions.

Participants in the study will receive Trifluridine/tipiracil as part of their first-line treatment for their cancer. The study will monitor the safety of this treatment over a period of time, specifically looking for any severe side effects. The trial will also assess how well the treatment controls the cancer, including measuring the disease control rate after two months of treatment. Other medications involved in the study include Nivolumab, Panitumumab, Bevacizumab, Trastuzumab, and Oxaliplatin, which may be used in combination with Trifluridine/tipiracil depending on the specific needs of the patient.

The study will last for several years, with regular assessments to check the health-related quality of life of the participants. This will be done using specific questionnaires designed for patients with colorectal or gastroesophageal cancer. The goal is to ensure that the treatment not only controls the cancer effectively but also maintains a good quality of life for the patients involved in the trial.

The purpose of this study is to evaluate how effective this combination of treatments is as a first-line therapy for patients with this specific type of colorectal cancer that shows a high level of immune cells within the tumor. The study will monitor patients over a period of time to see how many remain alive and without disease progression after 10 months. This is a non-randomized, multicenter study, meaning that all participants will receive the same treatment, and the study is conducted at multiple locations.

Participants in the study will receive the treatments through intravenous infusions, which means the medications are delivered directly into the bloodstream through a vein. The study will last for up to 24 months, during which time the patients’ health and response to the treatment will be closely monitored. The study aims to provide valuable insights into the effectiveness of combining chemotherapy and immunotherapy for treating this type of cancer.

The purpose of the study is to evaluate the overall survival of patients receiving the combination of XL092 and atezolizumab compared to those receiving regorafenib. Participants in the study will be randomly assigned to receive either the new combination treatment or the existing medication. The study will be conducted over a period of approximately 73 weeks, during which participants will receive their assigned treatment and be monitored for their response to the therapy. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments being studied.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the progression of their cancer. The study aims to provide valuable information on the effectiveness and safety of the new treatment combination, potentially offering new hope for patients with metastatic colorectal cancer. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.